Target Name: LOC105369663
NCBI ID: G105369663
Review Report on LOC105369663 Target / Biomarker Content of Review Report on LOC105369663 Target / Biomarker
LOC105369663
Other Name(s): uncharacterized LOC105369663 | Uncharacterized LOC105369663

LOC105369663: A Drug Target / Disease Biomarker

LOC105369663 is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. It is a member of the superfamily of nucleotide-binding proteins (NBP), which are a type of transmembrane protein that can interact with various nucleotides, including DNA, RNA, and proteins.

LOC105369663 is characterized by its unique molecular structure, which consists of a long N-terminus, a middle transmembrane region, and a C-terminus that is involved in protein-protein interactions. The protein is also known for its ability to interact with small molecules, such as drugs, toxins, and other substances that can affect the function of the cell.

Recent studies have identified LOC105369663 as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because the protein is involved in various cellular processes that are important for the function of the cell, and drugs that can disrupt these processes may have therapeutic benefits.

One of the key reasons for the potential of LOC105369663 as a drug target is its location in the cell. The protein is expressed in a variety of tissues, including the brain, which is home to many of the cell types that are responsible for maintaining the body's internal balance and regulating various physiological processes. As a result, drugs that can affect the function of LOC105369663 in the brain could have a wide range of therapeutic applications, including the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Another reason for the potential of LOC105369663 as a drug target is its ability to interact with a variety of small molecules, including drugs that can affect the function of the cell. Many drugs that are used to treat a wide range of diseases work by disrupting the function of specific proteins, and LOC105369663 is no exception. For example, LOC105369663 has been shown to interact with a variety of small molecules, including drugs that are used to treat everything from anxiety and depression to cancer and neurodegenerative diseases.

Finally, LOC105369663 is also a good candidate as a biomarker for certain diseases because of its expression in various tissues and its ability to interact with small molecules. This means that the protein can be used as a diagnostic tool for diseases that affect the brain, as well as for diseases that affect other tissues. For example, LOC105369663 has been shown to be expressed in the brain and has been used as a biomarker for a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In conclusion, LOC105369663 is a protein that is expressed in various tissues of the body and is involved in various cellular processes that are important for the function of the cell. Its unique molecular structure and ability to interact with small molecules make it a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, LOC105369663 is a promising target for future research and clinical development.

Protein Name: Uncharacterized LOC105369663

The "LOC105369663 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC105369663 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC105369689 | LOC105369698 | LOC105369705 | LOC105369709 | LOC105369710 | LOC105369732 | LOC105369735 | LOC105369736 | LOC105369743 | LOC105369749 | LOC105369750 | LOC105369761 | LOC105369765 | LOC105369772 | LOC105369775 | LOC105369777 | LOC105369780 | LOC105369781 | LOC105369798 | LOC105369806 | LOC105369818 | LOC105369823 | LOC105369830 | LOC105369833 | LOC105369835 | LOC105369838 | LOC105369843 | LOC105369844 | LOC105369850 | LOC105369862 | LOC105369869 | LOC105369879 | LOC105369890 | LOC105369896 | LOC105369923 | LOC105369927 | LOC105369928 | LOC105369944 | LOC105369958 | LOC105369965 | LOC105369976 | LOC105369998 | LOC105370002 | LOC105370003 | LOC105370011 | LOC105370025 | LOC105370027 | LOC105370032 | LOC105370050 | LOC105370073 | LOC105370076 | LOC105370108 | LOC105370109 | LOC105370113 | LOC105370115 | LOC105370127 | LOC105370128 | LOC105370134 | LOC105370135 | LOC105370165 | LOC105370168 | LOC105370174 | LOC105370176 | LOC105370182 | LOC105370204 | LOC105370214 | LOC105370222 | LOC105370243 | LOC105370259 | LOC105370262 | LOC105370273 | LOC105370275 | LOC105370286 | LOC105370302 | LOC105370311 | LOC105370312 | LOC105370321 | LOC105370324 | LOC105370328 | LOC105370355 | LOC105370359 | LOC105370384 | LOC105370399 | LOC105370420 | LOC105370429 | LOC105370438 | LOC105370452 | LOC105370455 | LOC105370470 | LOC105370476 | LOC105370481 | LOC105370497 | LOC105370500 | LOC105370504 | LOC105370507 | LOC105370519 | LOC105370529 | LOC105370536 | LOC105370544 | LOC105370546